TORL BioTherapeutics Announces $158 Million Oversubscribed Series B-2 Financing to Advance the Clinical Development of its Novel Antibody-Drug Conjugate (ADC) Oncology Pipeline
$158M Series B-2 Financing led by Deep Track Capital, with new participation from leading global biotechnology investors including RA Capital Management,...
Source: prnewswire.com